Elironrasib + Daraxonrasib
Phase 1/2Recruiting 0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-Small Cell Lung Cancer (NSCLC)
Conditions
Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
Trial Timeline
Nov 14, 2023 → Jun 1, 2029
NCT ID
NCT06128551About Elironrasib + Daraxonrasib
Elironrasib + Daraxonrasib is a phase 1/2 stage product being developed by REVOLUTION Medicines for Non-Small Cell Lung Cancer (NSCLC). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06128551. Target conditions include Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma.
What happened to similar drugs?
20 of 20 similar drugs in Non-Small Cell Lung Cancer (NSCLC) were approved
Approved (20) Terminated (2) Active (0)
Hype Score Breakdown
Clinical
9
Activity
15
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06128551 | Phase 1/2 | Recruiting |
Competing Products
20 competing products in Non-Small Cell Lung Cancer (NSCLC)